Bruton tyrosine kinase inhibitors (BTKi) therapies in chronic lymphocytic leukemia (CLL): Review of multiple trials data for incidence of lymphocytosis and designation of partial response with lymphocytosis (PRL).

Jayant Narang,Christiana Caplan,Katarina Ludajic,Sambit Ray,Surabhi Bajpai,Shweta Narang,Rudresh Jarecha,Manish Sharma,Oliver Bohnsack,Bruce D. Cheson

Bruton tyrosine kinase inhibitors (BTKi) therapies in chronic lymphocytic leukemia (CLL): Review of multiple trials data for incidence of lymphocytosis and designation of partial response with lymphocytosis (PRL).

2021

Jayant Narang
Christiana Caplan
Katarina Ludajic
Sambit Ray
Surabhi Bajpai
Shweta Narang
Rudresh Jarecha
Manish Sharma
Oliver Bohnsack
Bruce D. Cheson

e19502Background: In trials with BTKi, lymphocytosis alone may not be a sign of progression but rather treatment related redistribution of lymphocytes from tissues into the peripheral blood (Cheson...

Keywords:

Medicine
Partial Response with Lymphocytosis
Incidence (epidemiology)
Chronic lymphocytic leukemia
Lymphocytosis
Immunology
Bruton's tyrosine kinase
peripheral blood

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations